Dermatology Times

MAY 30, 2024

Novartis announced late-breaking data for the BTK inhibitor at the 2024 European Academy of Allergy and Clinical Immunology Congress.

Sustainability 73

Sustainability Safety Clinic 73

Dermatology Times

SEPTEMBER 25, 2023

Lilia Correa-Selm, MD, FAAD, FACMS, reviews the clinical trial data relating to the EVRIANCE study examining the use of vismodegib treatment in patients with locally advanced basal cell carcinoma, highlighting key efficacy and safety endpoints.

Safety 36

Safety Clinic Treatments 36

Dermatology Times

APRIL 19, 2024

Researchers examined local skin reactions of a topical gel inhibiting cytosolic phospholipase A2 both in-clinic and remotely.

Technology 83

Technology Safety Clinic 83

The Dermatology Digest

MAY 22, 2024

The first patient has been dosed in Zai Lab’s global Phase 2 clinical trial of ZL-1102, a topical anti-IL-17 investigational therapy for the treatment of mild to moderate chronic plaque psoriasis. Secondary objectives include efficacy throughout the treatment period, safety, tolerability, pharmacokinetics and anti-drug antibody (ADA).

Clinic 36

Clinic Therapy Safety Treatments 36

Dermatology Times

MARCH 10, 2024

Shawn Kwatra, MD, presented late-breaking data at AAD 2024 on the largest prurigo nodularis and nemolizumab clinical trial, OLYMPIA.

Safety 78

Safety Clinic 78

Dermatology Times

JUNE 2, 2024

Raj Chovatiya, MD, PhD, focused on understanding JAK inhibitors, discussing their clinical use and safety profiles for effective patient communication.

Safety 73

Safety Clinic 73

Dermatology Times

JUNE 10, 2024

Phase 3 clinical results showed that the safety and tolerability profiles were consistent with those observed in the original pivotal trials.

Safety 74

Safety Clinic 74

The Dermatology Digest

AUGUST 13, 2024

More data will be needed to define the safety profile of JAK inhibitors in Down syndrome, and we look forward to the completion of the trial and analysis of the full dataset.”

Clinic 74

Clinic Safety Dermatitis Medical 74

Dermatology Times

APRIL 5, 2024

Researchers reviewed the efficacy and safety of omalizumab in patients with severe CSU in a routine clinical practice setting.

Safety 74

Safety Clinic 74

Dermatology Times

JANUARY 4, 2024

The BLA submission for DMB-3115 is rooted in phase III multi-regional clinical trials focusing on plaque psoriasis patients. The results demonstrated a high similarity between DMB-3115 and ustekinumab in terms of quality, safety, and efficacy.

Safety 78

Safety Clinic 78

Dermatology Times

OCTOBER 12, 2023

Clinical response was maintained at 73.2% for PASI-75 in POETYK PSO long-term extension trial.

Safety 78

Safety Clinic 78

The Dermatology Digest

APRIL 12, 2024

Recent cases where possibly counterfeit neurotoxins in Illinois and Tennessee led to a cluster of illnesses resembling Botulism highlight the need to strengthen patient safety through increased oversight of medical care in all settings, according to the American Society for Dermatologic Surgery Association (ASDSA).

Safety 69

Safety Surgery Medical Training 69

The Dermatology Digest

JULY 14, 2024

CUTISS AG’s denovoSkin performed well in a Phase 2 clinical trial of patients undergoing reconstructive skin surgery for various conditions, according to an interim analysis of the data. Following the announced positive primary endpoint in Q1 2023, the one-year readout evaluated long term safety and scar quality.

Surgery 73

Surgery Scarring Safety Clinic 73

The Dermatology Digest

FEBRUARY 14, 2024

“We are thankful to the patients and medical experts whose insights informed our clinical trials, which assessed nemolizumab’s ability to reduce the symptoms of itch and skin lesions. In the ARCADIA program, nemolizumab clinically improved skin lesions and rapidly improved itch and sleep disturbance.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

AUGUST 30, 2024

The safety profile of pembrolizumab in this trial was consistent with the drug’s established safety profile. The primary endpoint is RFS, and key secondary endpoints include OS and safety. The DMC stated that the study be stopped as the risk/benefit profile did not support continuing it.

Surgery 36

Surgery Safety Therapy Innovations 36

The Dermatology Digest

JUNE 5, 2024

The randomized, double-blind, vehicle-controlled trial will evaluate the safety and efficacy of once-daily VYN201 topical gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks. Check out TDD’s one-on-one interview with Iain Stuart, PhD , Chief Scientific Officer at Vyne Therapeutics.

Safety 73

Safety Office Facials Therapy 73

Dermatology Times

OCTOBER 2, 2023

No concerns were cited about the clinical data package, safety, or label of lebrikizumab.

Safety 78

Safety Clinic 78

Dermatology Times

JUNE 19, 2024

Dermatologists provide clinical insights on how they discuss atopic dermatitis treatment options, considerations, and safety concerns with patients who are pregnant or of childbearing age.

Treatments 36

Treatments Dermatitis Safety Clinic 36

The Dermatology Digest

MARCH 18, 2024

Srinivas Sidgiddi, MD, Vice President, Research & Development at Journey Medical, adds, “The NDA submission is supported by positive data from Journey Medical’s two DFD-29 Phase 3 clinical trials for the treatment of rosacea.

Rosacea 74

Rosacea Medical Office Clinic 74

The Dermatology Digest

APRIL 4, 2024

The sBLA in moderate-to-severe HS is supported by data from the Phase 3 BE HEARD I and BE HEARD II studies where Bimzelx demonstrated clinically meaningful improvements in Hidradenitis Suppurativa Clinical Response-50 (HiSCR50) vs. placebo at Week 16, the primary endpoint. Bimzelx was approved in the U.S. In the U.S.,

Safety 57

Safety Injections Clinic Therapy 57

The Dermatology Digest

FEBRUARY 11, 2024

A meta-analysis of 45 randomized clinical trials comprised of 12,996 patients disclosed neither an increased risk of major cardiovascular events (MACE) such as heart attack and stroke) nor of venous thromboembolic events (VTE). This particular study did not address other safety concerns, such as all-cause mortality, infections, or cancer.

Safety 74

Safety Dermatology Clinic Therapy 74

The Dermatology Digest

JULY 16, 2024

is starting its global Phase 3 program, consisting of two Phase 3 trials (EMBARQ-CSU1 and EMBARQ-CSU2) designed to establish the efficacy and safety of barzolvolimab in adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. Celldex Therapeutics, Inc.

Safety 36

Safety Clinic Dermatitis Dermatology 36

Atelier Esthetique Institute of Esthetics

DECEMBER 5, 2023

Accrediting committees ensure that the quality and safety of your school is approved and noted by outside bodies. Atelier Esthetique has a clinic where our students can work for the general public. Thankfully, Atelier Esthetique Institute can help with our robust curriculum.

Esthetician 148

Esthetician Esthetics Education Training 148

The Dermatology Digest

FEBRUARY 22, 2024

DermBiont has completed enrollment in a Phase 2b clinical trial of SM-020 gel 1.0% We are pleased to have completed enrollment in our CT-213 clinical trial evaluating SM-020 gel 1.0% for the treatment of seborrheic keratoses. “We for the treatment of SK lesions, the most common benign tumors of the skin,” shares Karl Beutner, M.D.,

Safety 36

Safety Clinic Office Hyperpigmentation 36

The Dermatology Digest

FEBRUARY 22, 2024

DermBiont has completed enrollment in a Phase 2b clinical trial of SM-020 gel 1.0% We are pleased to have completed enrollment in our CT-213 clinical trial evaluating SM-020 gel 1.0% for the treatment of seborrheic keratoses. “We for the treatment of SK lesions, the most common benign tumors of the skin,” shares Karl Beutner, M.D.,

Safety 36

Safety Clinic Office Hyperpigmentation 36

The Dermatology Digest

JUNE 12, 2024

The safety and efficacy of Nuceiva was evaluated through the company’s TRANSPARENCY clinical program – three Phase III trials including the largest head-to-head aesthetic pivotal study versus Botox (onabotulinumtoxinA) to date, and two long-term safety studies. Side effects were similar to others in this class of medicine.

Safety 36

Safety Branding Facials Clinic 36

The Dermatology Digest

AUGUST 14, 2024

s VP-315 is showing promise in the treatment of basal cell carcinoma, according to Part 2 of its Phase 2 clinical trial. Patients may be cured with simple injections of VP-315,” adds Jonathan Kantor, MD, a dermatologist and Mohs surgeon at Florida Center for Dermatology, which was the leading enrollment site for the clinical study.

Safety 36

Safety Pharmaceutical Clinic Dermatology 36

The Dermatology Digest

AUGUST 13, 2024

FDA The approval is based on positive results from the phase III OLYMPIA clinical trials – the largest clinical trial program conducted in this condition to date – in which nemolizumab demonstrated significant and clinically meaningful improvements in itch and skin nodules at Week 16, with rapid reductions in itch observed as early as Week 4.

Dermatitis 36

Dermatitis Safety Clinic Dermatology 36

The Dermatology Digest

FEBRUARY 16, 2024

The safety profile of dupilumab in CSU was generally consistent with the known safety of Dupixent in its approved dermatological indications. The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.)

Pharmaceutical 36

Pharmaceutical Safety Dermatitis Therapy 36

The Dermatology Digest

AUGUST 21, 2024

TMB-001 did not meet the primary and key secondary endpoints in a randomized, double-blind period of the phase 3 ASCEND clinical trial of congenital ichthyosis. The trial results do not support submission of a New Drug Application to the U.S. Food and Drug Administration, according to Leo Pharma and Timber Pharmaceuticals.

Pharmaceutical 36

Pharmaceutical Clinic Office Safety 36

New Age Spa Institute

APRIL 18, 2024

This regulation ensures that all laser treatments are conducted with a high level of expertise and caution, minimizing risks and protecting patient safety. This allows estheticians to perform IPL treatments independently in spas and clinics, provided they have received the appropriate training and certification.

Legal 52

Legal Hair Removal Safety Esthetician 52

US Dermatologt Partners

JUNE 1, 2024

4 Clinical Data Supporting Apremilast In a phase 3 trial involving 595 patients with mildtomoderate plaque psoriasis inadequately controlled or intolerant to at least 1 topical therapy, apremilast demonstrated significant improvements. 7 Both apremilast and deucravacitinib have manageable safety profiles.

Therapy 41

Therapy Injections Safety Management 41

The Dermatology Digest

JULY 26, 2024

The CRL did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab. The post FDA Accepts BLA Resubmission of Cosibelimab for the Treatment of Advanced cSCC appeared first on The Dermatology Digest.

Treatments 36

Treatments Surgery Safety Clinic 36

Dermatology Times

DECEMBER 21, 2023

They also address the safety, tolerability, and comfortability aspects associated with the use of this novel TYK-2 inhibitor, drawing insights from long-term clinical trial data.

Safety 36

Safety Clinic Dermatology Treatments 36

The Dermatology Digest

AUGUST 15, 2024

All nine treated BCCs (1 superficial, 4 nodular, and 4 infiltrating) across seven enrolled subjects to date showed “prompt, visible, and robust” tumor responses during treatment with SM-020 1% twice daily for 28 days, resulting in partial or total reduction of clinically visible tumor. and CEO of DermBiont, in a news release.

Clinic 36

Clinic Scarring Office Safety 36

The Dermatology Digest

MAY 16, 2024

This grant will fund a collaborative effort to investigate the safety, tolerability, efficacy, and durability of response of subcutaneous administration of dupilumab in pediatric patients with extensive alopecia areata, defined as affecting at least 30% of the scalp.

Eczema 69

Eczema Dermatitis Innovations Safety 69

The Dermatology Digest

MARCH 9, 2024

Safety in the FRONTIER 2 long-term extension study (week 16 through Week 52) was found to be consistent with FRONTIER 1. J&J has initiated the Phase 2b ANTHEM-UC study to evaluate the safety and effectiveness of JNJ-2113 compared with placebo in participants with moderately to severely active ulcerative colitis. at 52 weeks).

Sustainability 36

Sustainability Safety Dermatology Clinic 36